Literature DB >> 8456888

Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study.

I Wiklund1, J Karlberg, L A Mattsson.   

Abstract

OBJECTIVE: The effect of transdermal estradiol and placebo therapy on the quality of life of postmenopausal women was compared in a randomized trial over 12 weeks. STUDY
DESIGN: Two hundred forty-two women were randomized, and 223 were analyzed for efficacy (n = 112 for estradiol and n = 111 for placebo). The quality of life was assessed by means of a battery of standard questionnaires.
RESULTS: Quality of life improved after both therapies, but health-related quality of life (p = 0.0003) and well being (p = 0.003) improved more after transdermal estradiol therapy than after placebo. This was also the case for all specific climacteric aspects, including sexual problems (p < 0.0001) and dysfunction (p = 0.01), at comparison with placebo. Self-rated symptom relief was more pronounced with estrogen therapy than with placebo (p < 0.0001).
CONCLUSION: It was concluded that estradiol therapy was superior to placebo in relieving symptoms and improving quality of life.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456888     DOI: 10.1016/s0002-9378(12)90828-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  35 in total

Review 1.  "Extracts from "Clinical evidence": Menopausal symptoms.

Authors:  J Rymer; E P Morris
Journal:  BMJ       Date:  2000-12-16

2.  The ethics of aggregation and hormone replacement therapy.

Authors:  A D Lyerly; E R Myers; R R Faden
Journal:  Health Care Anal       Date:  2001

Review 3.  Hormonal replacement therapy.

Authors:  Regine Sitruk-Ware
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

4.  Hysterectomy status, estrogen use and quality of life in older women: the Rancho Bernardo study.

Authors:  Donna Kritz-Silverstein; Denise G Von Muhlen; Theodore G Ganiats; Elizabeth Barrett-Connor
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

Review 5.  Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women.

Authors:  John H Morrison; Roberta D Brinton; Peter J Schmidt; Andrea C Gore
Journal:  J Neurosci       Date:  2006-10-11       Impact factor: 6.167

6.  Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression.

Authors:  B Saletu; N Brandstätter; M Metka; M Stamenkovic; P Anderer; H V Semlitsch; G Heytmanek; J Huber; J Grünberger; L Linzmayer
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

Review 7.  Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders.

Authors:  Anna-Carin N-Wihlbäck; Inger Sundström-Poromaa; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2005-12-15       Impact factor: 4.530

Review 8.  Role of estrogen in the aetiology and treatment of mood disorders.

Authors:  U Halbreich; L S Kahn
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 9.  The impact of fragility fracture on health-related quality of life : the importance of antifracture therapy.

Authors:  Ted Xenodemetropoulos; Shawn Davison; George Ioannidis; Jonathan D Adachi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  Differences in free estradiol and sex hormone-binding globulin in women with and without premenstrual dysphoric disorder.

Authors:  Susan Thys-Jacobs; Don McMahon; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2007-10-23       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.